When scientists and research experts meet in Grenada, Spain, next month, aTyr Pharma will present research on adult patients with muscular dystrophy.
- PR Newswire•2 days agoaTyr Pharma Announces Presentation at the 21st International Annual Congress of the World Muscle Society
SAN DIEGO, Sept. 29, 2016 /PRNewswire/ -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare ...
- PR Newswire•9 days agoaTyr Pharma Appoints Industry Veteran in Novel Biology Biologics, David J. King, PhD, as Senior Vice President, Research
SAN DIEGO, Sept. 21, 2016 /PRNewswire/ -- aTyr Pharma, Inc. (LIFE), today announced that David J. King, PhD, has joined the company as Senior Vice President, Research. Dr. King will lead aTyr's research and preclinical efforts to advance its Physiocrine biology and support the clinical development of meaningful medicines that target immune and tissue homeostatic pathways for patients with various severe and rare diseases. "Dr. King is uniquely qualified to help us execute on our mission to bring Physiocrine-based therapeutic candidates to patients with severe and rare diseases," said John Mendlein, PhD, Chief Executive Officer of aTyr Pharma.
aTyr Pharma Inc. (LIFE)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||2.86 x 400|
|Ask||3.30 x 300|
|Day's Range||3.15 - 3.30|
|52wk Range||2.48 - 13.26|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-1.27|
|Avg Vol (3m)||221,721|
|Dividend & Yield||N/A (N/A)|